We are searching data for your request:
Upon completion, a link will appear to access the found materials.
HYPOSTAT study examines precision radiation in prostate cancer
Many men experience prostate cancer throughout their lives, and the prospects of successful treatment have improved significantly in recent years. Experts are hoping for further advances in therapy from what is known as CyberKnife technology, which is currently being tested in Germany as part of the HYPOSTAT study.
The new technology of short-term high-dose radiation surgery using a robot-assisted linear accelerator for radiosurgery - "CyberKnife" for short - offers hope for significantly more efficient treatment of prostate cancer, with better chances of success and fewer side effects. The HYPOSTAT study is now to be expanded accordingly and the use of the new treatment method will be tested on a larger number of patients.
Fewer individual irradiations required
The study is being carried out jointly by scientists from the University Medical Center Schleswig-Holstein (UKSH), the University Medical Center Frankfurt, the University Medical Center Rostock, the University Medical Center Greifswald and the Sapphire Radiosurgery Centers. UKSH reports that new grants have been approved and new centers and new inclusion criteria for younger patients have been added. Precision irradiation allows the total number of individual irradiations to be reduced to five sessions within one to two weeks.
Treatment method in the US for years in testing
Basically, "extremely hypofractionated radiation surgery for prostate cancer is not a new treatment concept," reports the University Medical Center Schleswig-Holstein. This treatment technique has been actively tested in the United States for over 15 years. The approach that high-dose short-term radiation therapy for the prostate is biologically more advantageous than conventional fractional radiation therapy is also based on the good results of high-dose brachytherapy that have been achieved on the UKSH campus in Kiel since the 1990s.
Positive results in comparative study
A direct comparison study between CyberKnife radiation surgery and conventionally fractionated radiation therapy was only recently published, which found significantly fewer side effects with the new treatment method. "The data from Poland showed a significantly lower grade 2 side effect rate of 3-12 percent for radiation surgery compared to 18-42 percent for conventional radiation therapy," the UKSH said. The evaluation of the tumor control is still pending, but the biological radiation dose in the prostate was significantly higher for radiation surgery treatments, which gives hope for better treatment results.
New technology is only just beginning in this country
In the first evaluation of the data from 400 treated patients in Poland, a median follow-up period of 15 months resulted in a "tumor control rate of 97.75 percent with only one percent local recurrence rate in the prostate", reports the UKSH. The researchers were also able to demonstrate that the PSA course after radiation surgery with additional hormone therapy does not differ from that without hormone therapy. According to the UKSH, additional hormone therapy after radiation surgery can be dispensed with. "The data from Poland confirm our assumptions and support the HYPOSTAT study even more," says study leader Professor Dr. Jürgen Dunst, Director of the Clinic for Radiation Therapy at the UKSH. So far, all patients have been very satisfied and, as expected, the side effects were minor. "But compared to other countries, we are unfortunately only at the beginning," emphasizes the expert. (fp)